Diabetes & Metabolism Journal

Original Article

Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus: Hye Soo Chung, Moon-Kyu Lee; Diabetes Metab J. 2011;35(4):411-417. Published online August 31, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.4.411

3,418 View
73 Download
12 Crossref

Background

To evaluate the clinical efficacy of sitagliptin for reducing plasma glucose levels in Korean subjects with type 2 diabetes mellitus during a 14-week treatment period.

Methods

Our study design involved the addition of 100 mg sitagliptin once-daily to three ongoing combination therapy regimens and changing from glimepiride and metformin to sitagliptin and metformin.

Results

The addition of sitagliptin 100 mg/day produced a statistically significant reduction in mean HbA1c level (mean HbA1c reduction of 0.99±0.85%, P<0.01). In the group taking a combination of sitagliptin and metformin (n=143, initial mean HbA1c level=7.48%), the reductions in HbA1c, 2-hour postprandial glucose, and fasting glucose levels were 0.72±0.76% (P<0.01), 47±65 mg/dL (P<0.01), and 15±44 mg/dL (P<0.01), respectively. In the group taking a combination of sitagliptin, glimepiride, and metformin (n=125, initial mean HbA1c level=8.42%), the reductions in HbA1c, 2-hour postprandial glucose, and fasting glucose levels were 1.09±0.86% (P<0.01), 62±64 mg/dL (P<0.01), and 31±45 mg/dL (P<0.01), respectively. In the group taking a combination of sitagliptin, glimepiride, metformin, and α-glucosidase inhibitor (n=63, initial mean HbA1c level=9.19%), the reductions in HbA1c, 2-hour postprandial glucose, and fasting glucose levels were 1.27±0.70% (P<0.01), 72±65 mg/dL (P<0.01), and 35±51 mg/dL (P<0.01), respectively. In the group that had previous hypoglycemic events and that changed from glimepiride to sitagliptin, HbA1c level did not change but fasting glucose increased significantly (14±29 mg/dL, P<0.01).

Conclusion

Sitagliptin combination therapy for 14 weeks significantly improved glycemic control and was well-tolerated in Korean subjects with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

Impact of Treviamet® & Treviamet XR® on quality of life besides glycemic control in type 2 DM patients
Asima Khan, Muhammad Adnan Kanpurwala, Riasat Ali Khan, Najum F. Mahmudi, Verumal Lohano, Shakeel Ahmed, Majid Khan, Fareed Uddin, Syed Mohammad Ali, Maliha Saghir, Syed Hussain Baqar Abidi, Jahanzeb Kamal
BMC Endocrine Disorders.2023;[Epub] CrossRef
Efficacy and safety of sitagliptin/metformin fixed‐dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double‐blind study
Sang Soo Kim, In Joo Kim, Kwang Jae Lee, Jeong Hyun Park, Young Il Kim, Young Sil Lee, Sung Chang Chung, Sang Jin Lee
Journal of Diabetes.2017; 9(4): 412. CrossRef
Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
Hyun Min Kim, Jung Soo Lim, Byung-Wan Lee, Eun-Seok Kang, Hyun Chul Lee, Bong-Soo Cha
Endocrinology and Metabolism.2015; 30(1): 84. CrossRef
Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta‐analysis
JM. Amate, T. Lopez‐Cuadrado, N. Almendro, C. Bouza, Z. Saz‐Parkinson, R. Rivas‐Ruiz, J. Gonzalez‐Canudas
International Journal of Clinical Practice.2015; 69(3): 292. CrossRef
Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
Ye An Kim, Won Sang Yoo, Eun Shil Hong, Eu Jeong Ku, Kyeong Seon Park, Soo Lim, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi
Diabetes & Metabolism Journal.2015; 39(6): 489. CrossRef
Sitagliptin for Elderly Patients Aged 75 Years or Older with Inadequately Controlled Type 2 Diabetes with Common Antidiabetes Treatments
Katsunori Suzuki, Yurie Mistuma, Takaaki Sato, Mariko Hatta
International Journal of Clinical Medicine.2015; 06(09): 672. CrossRef
Short‐ and long‐term effect of sitagliptin after near normalization of glycemic control with insulin in poorly controlled Japanese type 2 diabetic patients
Keiko Fujisawa, Tetsuyuki Yasuda, Hideaki Kaneto, Naoto Katakami, Mayumi Tsuji, Fumiyo Kubo, Shugo Sasaki, Kazuyuki Miyashita, Toyoko Naka, Ryuuichi Kasami, Akio Kuroda, Munehide Matsuhisa, Iichiro Shimomura
Journal of Diabetes Investigation.2014; 5(5): 548. CrossRef
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
Chun-Jun Li, Xiao-Juan Liu, Lian Bai, Qian Yu, Qiu-Mei Zhang, Pei Yu, De-Min Yu
Diabetology & Metabolic Syndrome.2014;[Epub] CrossRef
Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes
Sun Ok Song, Kwang Joon Kim, Byung‐Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
Journal of Diabetes Investigation.2014; 5(5): 554. CrossRef
Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy
Keiji Yoshioka, Haruhiko Isotani, Shin-ichiro Ohashi, Minoru Imamura
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2013; 7(1): 32. CrossRef
Glimepiride Strongly Enhances the Glucose-Lowering Effect in Triple Oral Antidiabetes Therapy with Sitagliptin and Metformin for Japanese Patients with Type 2 Diabetes Mellitus
Keiko Arai, Hajime Maeda, Sin-ichiro Sirabe, Ritsuko Yamamoto, Mikio Yamauchi, Tetsuyuki Hirao, Setsuko Hirao, Koichi Hirao
Diabetes Technology & Therapeutics.2013; 15(4): 335. CrossRef
Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy
Mitsuyoshi Takahara, Toshihiko Shiraiwa, Hideaki Kaneto, Naoto Katakami, Taka-aki Matsuoka, Iichiro Shimomura
Endocrine Journal.2012; 59(12): 1131. CrossRef

First
Prev
Page of 1
Next
Last

Search